Ribbon Biolabs Raises Eur 18 Million Series A Financing Enabling Commercial Scale Production Facilities And Us Expansion For Dna Synthesis Technology
Ribbon Biolabs Raises Eur 18 Million Series A Financing Enabling Commercial Scale Production Facilities And Us Expansion For Dna Synthesis Technology
01/31/22, 10:00 AM
Location
viennaMoney raised
€18 million
Industry
biotechnology
health care
Round Type
series a
Ribbon Biolabs, the DNA synthesis company, today announced the successful close of EUR 18 million in its Series A funding round from a consortium of European and US investors led by Hadean Ventures and with participation from Lansdowne Partners, Helicase Venture as well as several undisclosed investors. Existing investors IST cube and tecnet equity also joined in the round.
Company Info
Location
vienna, illinois, united states
Additional Info
Ribbon Biolabs is a synthetic biology company advancing a new technology for the automated synthesis of long DNA molecules to enable innovation in the life sciences. With its proprietary technology in place, Ribbon Biolabs aims to be an inflection point in the continuing growth of the Bio-Economy by becoming the leading partner for long DNA molecules.